Assert-IQ vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

VX1

by Volta Medical

AI Verdict

Assert-IQ provides long-term, continuous cardiac monitoring for diagnosing and managing suspected heart rhythm disorders. In contrast, VX1 is an AI software designed to assist electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures. While both operate within cardiology AI, they address distinct phases of patient care: diagnosis and long-term management versus intra-procedural guidance.

Choose Assert-IQ if…

Choose Assert-IQ if your patient presents with infrequent or paroxysmal symptoms suggestive of a cardiac arrhythmia that requires long-term, continuous monitoring for accurate diagnosis or ongoing management. This system is ideal for extended surveillance, providing up to six years of data and remote monitoring capabilities to capture elusive events and proactively alert clinicians.

View Assert-IQ →

Choose VX1 if…

Choose VX1 if you are an electrophysiologist performing atrial fibrillation or atrial tachycardia ablation procedures and seek real-time AI guidance to enhance procedural precision. This software integrates with existing EP lab systems to identify dispersed electrograms, aiming to reduce inter-operator variability and standardize outcomes during complex ablations.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	VX1
Pricing	Unknown	Contact for pricing
Deployment	Subcutaneously implanted device with mobile app connectivity	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Assert-IQ

Assert-IQ offers a broader scope of usability, including a minimally invasive insertion, remote monitoring capabilities, and a patient activator for symptom logging, making it user-friendly for both clinicians and patients over a long period. VX1's usability is focused on real-time integration into complex EP lab procedures, which is valuable for clinicians but less broad in its user interaction.

Clinical Value

VX1

While both offer significant clinical value, VX1's real-time AI guidance during complex atrial fibrillation and atrial tachycardia ablation procedures directly impacts procedural success and aims to reduce inter-operator variability and standardize outcomes. This direct, real-time intervention during a critical procedure provides a distinct and immediate clinical advantage in a high-stakes setting.

Pricing & Value

Tie

Both tools have opaque pricing models, requiring direct contact for institutional or enterprise pricing, and neither offers a free trial. Without specific pricing details or published return-on-investment studies for either product, it is not possible to definitively determine which offers better pricing or overall value.

Enterprise Readiness

Assert-IQ

Assert-IQ is developed by Abbott Medical, a large and established global healthcare leader, explicitly states HIPAA compliance, and targets large health systems. This background and explicit compliance information suggest a higher level of enterprise readiness compared to Volta Medical's VX1, which does not explicitly state HIPAA compliance or BAA in the provided facts.

Innovation

VX1

VX1 demonstrates a more cutting-edge application of AI by providing real-time, AI-guided identification of dispersed electrograms during complex cardiac ablation procedures, analyzing 3D anatomical and electrical maps. This real-time AI assistance during a live interventional procedure represents a significant advancement in precision medicine.

Support & Docs

Assert-IQ

Abbott Medical, as a large and established medical device company, provides extensive public resources including detailed manuals, guides, and dedicated remote care technical support for Assert-IQ. While Volta Medical offers training and support for VX1, the breadth and accessibility of support and documentation from Abbott are more comprehensive.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	VX1
Name	Assert-IQ	VX1
Company	Abbott Medical	Volta Medical
Description	The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.	Volta Medical's VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
Key Features	Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion	AI-guided real-time identification of dispersed electrograms (EGMs), Assists cardiologists during AFib and atrial tachycardia ablation procedures, Analyzes 3D anatomical and electrical maps of human atria, Compatible with most EP recording, 3D navigation systems, and mapping catheters, Designed to reduce inter-operator variability and standardize outcomes, Provides cycle length estimation from electrograms, Booster mode for increased sensitivity during AT or slow AF
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Surgical AI
Specialties	Cardiology, Internal Medicine	Cardiology

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and VX1.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application of Assert-IQ compared to VX1?

Assert-IQ is an insertable cardiac monitor (ICM) designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. In contrast, VX1 is an AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.

How do these tools integrate into existing clinical workflows and infrastructure?

Assert-IQ is a hybrid deployment system, involving a minimally invasive insertable device that uses Bluetooth Low Energy for data transmission to a secure cloud-based data platform, enabling remote monitoring and data export. VX1 is software integrated with existing electrophysiology (EP) lab mapping and recording systems, compatible with most EP recording, 3D navigation systems, and mapping catheters.

For which patient populations or procedural stages is each tool primarily intended?

Assert-IQ is intended for patients with suspected heart rhythm disorders requiring long-term monitoring for diagnosis and management, including those with unexplained symptoms like dizziness or palpitations, or those at risk for or diagnosed with atrial fibrillation. VX1 is specifically designed to assist cardiologists during the acute phase of AFib and atrial tachycardia ablation procedures.

What specific types of data and insights does each tool provide to aid clinical decision-making?

Assert-IQ provides long-term continuous cardiac monitoring data, advanced arrhythmia detection algorithms, proactive clinician alerts, and patient activator for symptom logging. VX1 offers AI-guided real-time identification of dispersed electrograms, analyzes 3D anatomical and electrical maps of human atria, and provides cycle length estimation from electrograms.

What is the duration of monitoring or intervention offered by each tool?

Assert-IQ provides long-term continuous cardiac monitoring, with options for battery life of at least three or six years. VX1, in contrast, provides real-time assistance during the specific duration of atrial fibrillation and atrial tachycardia ablation procedures.

What are the primary goals or intended benefits for physicians using each tool?

Assert-IQ aims to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders through comprehensive, long-term monitoring, reducing false positives and streamlining workflow. VX1 is designed to assist cardiologists during ablation procedures, with the goal of reducing inter-operator variability and standardizing outcomes by precisely pinpointing optimal ablation locations.